AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

TransMedics Group, Inc. Director's Dealing 2019

Dec 10, 2019

31201_dirs_2019-12-10_71cce4bb-9e47-40da-80ba-9bf59229c68d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TransMedics Group, Inc. (TMDX)
CIK: 0001756262
Period of Report: 2019-12-09

Reporting Person: UNITED THERAPEUTICS Corp (10% Owner)
Reporting Person: Lung Biotechnology PBC (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-12-09	Common Stock	S	500000	$18.75	Disposed	2053240	Indirect

Footnotes

F1: The securities reported as being indirectly beneficially owned by United Therapeutics Corporation are directly beneficially owned by Lung Biotechnology PBC. Lung Biotechnology PBC is a wholly-owned subsidiary of United Therapeutics Corporation.